3 completed, 2 active not recruiting, 1 not yet recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Active not recruiting 2, Not yet recruiting 1 |
Follow Chromosome Aberrations: new trials by email Literature Review of Chromosome Aberrations trials Research Report on Chromosome Aberrations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) Asciminib, Nilotinib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 568 | 2022-11-21 | 2026-08-26 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 405 | 2021-10-06 | 2026-08-28 |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Bosutinib, Imatinib - Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive | Phase 3 | Completed | Pfizer | 536 | 2014-07-15 | 2021-05-18 |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Imatinib, Radotinib - Leukemia, Leukemia, Myeloid | Phase 3 | Completed | Il-Yang Pharm. Co., Ltd. | 242 | 2011-08-01 | 2016-02-24 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Nilotinib - Chronic Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 421 | 2011-04-01 | 2016-03-03 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Philadelphia Chromosome (6) · Leukemia (3) · Bone Marrow Diseases (2) · Hematologic Diseases (2) · Leukemia, Myeloid (2) · Leukemia, Myeloid, Chronic-Phase (2) · Bronchiolitis Obliterans Syndrome (1) · Myeloproliferative Disorders (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Translocation, Genetic (1)
Chronic Disease (6) · Disease Attributes (6) · Hemic and Lymphatic Diseases (6) · Neoplasms (6) · Pathological Conditions, Signs and Symptoms (6) · Myeloproliferative Disorders (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Translocation, Genetic (5) · Bone Marrow Diseases (4) · Hematologic Diseases (4) · Leukemia, Myeloid (4) · Leukemia (3) · Bronchial Diseases (1)
nilotinib (4) · Imatinib Mesylate (3) · bosutinib (3) · Dasatinib (2) · asciminib (2) · 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide (1)
Novartis Pharmaceuticals (3) · Enliven Therapeutics (1) · Il-Yang Pharm. Co., Ltd. (1) · Pfizer (1)
Canada (4) · South Korea (4) · Australia (3) · Czechia (3) · France (3) · Germany (3) · Hungary (3) · India (3) · Israel (3) · Italy (3) · Malaysia (3) · Netherlands (3) · Singapore (3) · Slovakia (3) · South Africa (3)
PMID 28699641, PMID 28939746, PMID 29091516, PMID 33851349, PMID 35235189, PMID 35643868, PMID 36524980, PMID 37553873, PMID 38820078, PMID 41397287, PMID 42339511
2023 (1)